Wednesday, February 10, 2010, 1:15PM AEST - The Australian Stockmarket closes in 2 hours and 50 minutes.
To create a watchlist or portfolio of shares, Register

GenVec Inc. (GNVC)

8:00AM AEST: 1.72 USD  Up 0.04 (2.38%)  
 MORE ON GNVC 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 GenVec, Inc. (NGM:GNVC) Delayed quote dataEdit
Last Trade:1.72 USD
Trade Time: 8:00AM AEST
Change:Up 0.04 (2.38%)
Prev Close:1.68
Open:1.70
Bid:1.47 x 4500
Ask:1.88 x 1200
1y Target Est:4.00
Day's Range:1.68 - 1.74
52wk Range:0.33 - 3.34
Volume:1,641,271
Avg Vol (3m):3,662,130
Market Cap:182.90M
P/E (ttm):N/A
EPS (ttm):-0.22
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add GNVC to Portfolio   Download Data

 HEADLINES 
3 Stocks in a Tailspin
at Motley Fool (Fri, Feb 5)
10 Biotech Stocks on Clinical Trials Watch
at TheStreet.com (Thu, Feb 4)
Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering
PR Newswire (Tue, Feb 2)
GenVec to Present at the 12th Annual BIO CEO & Investor Conference
PR Newswire (Mon, Feb 1)
Biotech Stock Mailbag: Keryx Biopharmaceuticals
at TheStreet.com (Fri, Jan 29)
Wednesday's Biggest Stock Stars
at Motley Fool (Fri, Jan 29)
More Biotech Volatility: Celsius Holdings, Genvec
at Seeking Alpha (Thu, Jan 28)
GENVEC INC Files SEC form 8-K, Financial Statements and Exhibits
EDGAR Online (Thu, Jan 28)
Jackson Hewitt Tax Service, GenVec: Biggest Price Decliners (JTX, GNVC)
at The Wall Street Journal Online (Thu, Jan 28)
Conolog, Jackson Hewitt: Late Day Volume Plays
at TheStreet.com (Thu, Jan 28)
Jackson Hewitt Tax Service, GenVec: Biggest Price Decliners (MLP, GNVC)
at The Wall Street Journal Online (Thu, Jan 28)
More Headlines for GNVC...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.17
EPS Est (in 2 years) (Dec-10) :-0.18
Avg Rec (current)*:2.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III trial for first-line treatment of inop...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices